Pet Owners Tighten Belts, Sending Zoetis Shares Into a Tailspin

Zoetis misses Q1 earnings as US pet owners delay treatments, slashes 2026 outlook. Stock hits new low of €74.42 amid consumer caution.

The era of pet owners sparing no expense for their animals' health has come to an abrupt halt, and Zoetis is bearing the brunt of the shift. The animal health giant delivered a first-quarter earnings miss that sent its stock plunging by as much as 22%, marking a new 2026 low of €74.42. The sell-off accelerated after management slashed its full-year outlook, acknowledging that consumer caution has reached veterinary clinics.

Revenue for the first quarter came in at $2.26 billion, falling short of the $2.3 billion analysts had penciled in. Adjusted earnings per share of $1.53 also missed the consensus estimate of $1.61. The net income landed at $601 million. While the top line showed a modest year-on-year gain of roughly 2%, organic growth was flat — a clear sign that underlying demand is softening.

The trouble is concentrated in the US companion animal business, where revenue dropped 8% to $1.09 billion. Pet owners are increasingly price-sensitive, delaying treatments or switching to cheaper alternatives. Veterinary visits are declining, and competition in dermatology and parasite control has intensified, squeezing margins on Zoetis’s premium brands.

CEO Kristin Peck pointed to a growing reluctance among pet owners to spend freely, a trend that has forced the company to recalibrate its expectations. The international segment offered some relief, with revenue climbing 17%, and the livestock division proved resilient, growing 19% on robust demand from cattle, swine, and poultry farming. But those gains were not enough to offset the US weakness.

The revised guidance reflects the new reality. For the full year 2026, Zoetis now expects revenue between $9.68 billion and $9.96 billion, down from a previous range that topped out at $10.025 billion. Adjusted earnings per share are forecast at $6.85 to $7.00, compared with an earlier target of up to $7.10.

Despite the near-term headwinds, the company is banking on its pipeline to drive a recovery. More than a dozen potential blockbuster products are in development, and the acquisition of Neogen’s genomics business is on track to close in the second half of 2026. Strict cost controls are also being implemented to protect margins.

Investors, however, are focused on the immediate damage. The stock has now lost roughly 30% since the start of the year, and the new 52-week low underscores the depth of the market’s disappointment. Whether Zoetis can regain its footing will depend on how quickly pet owners return to the vet — and whether the company’s pipeline can deliver before patience runs out.